BID TerminalOpen complete report
Research library Healthcare

Back of Napkin

Mettler-Toledo International Inc. MTD

Three-pass checkedFiled since 2026-07-31

Written 2026-06-15. The company has filed a quarterly or annual report since, on 2026-07-31, so figures here predate its latest disclosure.

Mettler-Toledo is the highest-return business in the lab-and-industrial-instruments group, earning a 36% return on invested capital while the stock has fallen 24% from its 52-week high to roughly peer multiples.

The asymmetry is thin; this is a quality-at-fair-price buyback compounder, not a mispriced right-tail, and it works only if organic growth reverts toward mid-single-digits as the capex cycle turns.

Key data

Sector / industryHealthcare / precision instruments
FYE / countryDecember / US
Price / 52w range$1,154.47 / $1,023.05 to $1,525.17
Position vs MA50d SMA $1,206.62, 200d SMA $1,318.13
Market cap / EV≈$23.3B / ≈$25.5B
Revenue (TTM)≈$4.09B
EPS (TTM, GAAP)≈$43.14
Forward P/E (FY26E)24.8x
Beta1.26

MTD · price with moving averages

Daily · 6MWeekly · 3Y
$933$1091$1250$1408$1566 Sep '23Apr '24Nov '24Jun '25Jan '26Aug '26 BID
EMAs82140

Source: market data.

The business

Mettler-Toledo makes the precision instruments that sit on lab benches and factory floors: laboratory balances accurate to the microgram, pipettes, titrators, pH meters and thermal-analysis systems; industrial weighing, product-inspection and process-analytics gear; and the networked scales and labeling systems in grocery fresh-food departments. The segment doing most of the work is Laboratory, at 55.7% of FY2025 revenue ($2.24B), with Industrial at 39.2% ($1.58B) and Retail the remaining 5.1% ($206M). Geographically the book splits roughly Americas 40%, Asia 29%, Europe 27%. The model is razor-and-blade in disguise: an instrument is sold once, then consumables, calibration, spare parts and service contracts pull through for the life of the install, and that recurring tail now runs near half of sales at higher margins than the hardware.

The thing the financials do not show is the captive field-sales-and-service network. Mettler runs its own direct sales force in most markets rather than selling through distributors, which is expensive to build and is the real reason a 58% gross margin holds year after year: the company controls pricing and owns the service relationship. What changed over the last several quarters is demand timing, not the model. Laboratory and industrial customers, especially in China and in pharma and biotech, have deferred instrument purchases through a soft capital-spending cycle, which is why organic growth has run in the low-single-digits rather than the mid-single-digits Mettler posts in a normal year. Q1 2026, reported May 8, showed revenue of $947.1M, up 7.2% year-over-year, with GAAP EPS of $8.35 up 6.5%, an early read that the cycle is firming rather than breaking.

Inside the complete Back of Napkin

  1. 01The business
  2. 02The numbers
  3. 03Management
  4. 04The linchpins
  5. 05Closing
  6. 06Methodology

Continue with MTD

Get the complete Back of Napkin free.

Choose this as your free complete report. No card required.

Read the complete report